Exploring Geographic Variability in Cancer Prevalence in Eastern Morocco: A Retrospective Study over Eight Years

Manal Elidrissi Errahhali*, Mounia Elidrissi Errahhali*, Naima Abda, Mohammed Bellaoui *

Medical Biology Unit, Faculty of Medicine and Pharmacy of Oujda, University Mohammed the First, Oujda, Morocco

☯ These authors contributed equally to this work.
* bmbellaoui@gmail.com

Abstract

Background

Malignant diseases have been believed to be more common in some areas of Eastern Morocco, but until now, cancer patterns have not been reported for this region. In this paper we present for the first time the cancer prevalence analysis in Eastern Morocco.

Methods

Cross-sectional study carried out among all patients diagnosed and/or treated with cancer at the Hassan II Regional Oncology Center (ROC) since it was established in October 2005 until December 2012. The ROC is the only hospital specialized in cancer care in Eastern Morocco.

Results

A total of 8,508 cases of cancer were registered among residents in Eastern Morocco, with a female to male ratio of 2.1. The mean age at diagnosis was 53.9 ± 15.2 years (median age = 53 years). Thus, unlike in Western countries, cancer in Eastern Morocco afflicts younger population. The areas of Eastern Morocco did not differ significantly by mean age at diagnosis (p = 0.061). However, these regions differed significantly by sex ratio (p < 0.001). The highest sex ratio was observed in Figuig, with a female to male ratio of 3.1 (75.4% of the registered case were females), followed respectively by Taourirt, Oujda-Angad, Berkane, Nador-Driouch and Jerada. Clear variation in the distribution of cancer types between areas of Eastern Morocco was observed, both in males and females (p < 0.001). Furthermore, the areas of Eastern Morocco differed significantly by cancer prevalence (p < 0.001). The highest age-standardized five-year prevalence proportion was observed in Oujda-Angad with 420.2 per 100,000, followed respectively by Berkane (311.4), Jerada (287.8), Taourirt (269.3), Nador-Driouch (213.6) and Figuig (194.4). Trends in the five-year prevalence proportions decreased...
in Oujda-Angad, Berkane and Jerada throughout the study period, while an increasing trend was observed in Nador-Driouch, Taourirt and Figuig.

Conclusions
For the first time, our study presents the pattern and distribution of diagnosed cancers in Eastern Morocco. Our study illustrates substantial differences in cancer patterns between areas of Eastern Morocco. These findings are important for cancer control and highlight the need to develop program aiming at controlling and preventing the spread of major cancer sites in Eastern Morocco, particularly in areas with increased cancer prevalence rates.

Introduction
According to WHO, global cancer prevalence is growing at “alarming pace” [1]. In Morocco, cancer is one of the major health problems and it is the second leading cause of mortality after cardiovascular diseases with 10.7% of all deaths [2]. However, there is no national cancer reporting system in Morocco. There are only two population-based cancer registries at the present time, the Rabat and Casablanca registries [3–5]. However, in order to develop an effective national program for cancer control and prevention, it is essential to study the burden of cancer in each area of Morocco.

Eastern Morocco is the third largest region in Morocco, but there is still no population-based cancer registry until now. Located at the border between Morocco and Algeria and close to Europe, this region has been a hot spot throughout the history. Eastern Morocco is located in the north east of the kingdom of Morocco, and extends on an area of 82,820 km², which is equivalent of 11.6% of the national territory. According to the administrative division of 2009, Eastern Morocco is divided into one prefecture (Oujda-Angad) and six provinces (Nador, Driouch, Berkane, Taourirt, Jerada and Figuig) (Fig 1). According to the High Commission for Planning (HCP), Eastern Morocco had a population of over 2 million in 2013, which is equivalent to 6.2% of the total population of the Kingdom. The population is mainly urban (67% vs. 33% rural) and young, nearly 6 out of 10 people are under 30 years [6].

Determination of cancer prevalence is an important measure to study the burden of cancer [7–13]. Therefore, in this retrospective study, we report the geographic variability in cancer prevalence and patterns in Eastern Morocco over a period of eight years between 2005 and 2012.

Materials and Methods
Design of the study
This is a cross-sectional study carried out among all hospitalized or monitored patients for cancer at the Hassan II Regional Oncology Center (ROC) since October 2005 until December 2012. The ROC was established in October 2005 and is the only hospital specialized in cancer care in Eastern Morocco and it includes several units, such as surgery, chemotherapy, and radiotherapy.

Study population
The study population consists of all cancer cases that were registered at the ROC since it was established in October 2005 until December 2012. The majority (98%) of the cases were
microscopically verified. The registrations were considered microscopically verified when the diagnosis was based on malignant histological or cytological reports. We excluded from the study patients for whom the proof of cancer could not be made or the medical file is incomplete or unexploitable. The borderline tumors and cases of intraepithelial neoplasia were also excluded from the study. Patients who do not reside in Eastern Morocco or for whom the place of residence was not specified were also excluded from the analysis.

Data collection and cancer classification
The data were collected from patient medical records, pathology records and admission records. We followed the registration rules, defined by the International Agency for Research on Cancer (IARC). The registred cases were coded according to the third edition of the International Classification of Diseases for Oncology (ICD-O-3) [14]. For tabulation of results, these
were converted to the 10th revision of the ICD [15]. A form has been used for collecting information recorded on each case, such as the record number, name and surname of the patient, gender, age, place of residence, years of diagnosis, cancer site, and histological type.

Analysis

Data collection was performed on Excel. Statistical analysis was performed using SPSS software version 21.0. Initially, descriptive statistics were used to describe the distribution of cancer by age, sex and area. To evaluate differences between each area we used Chi2 to evaluate categorical variables (sex) and one-way analysis of variance (ANOVA) for continuous variables (age). The results were considered significant when \( p \) (degree of significance) is less than 0.05, very significant when \( p < 0.01 \) and highly significant when \( p < 0.001 \).

Total prevalence proportions (per 100,000) were calculated for each area of Eastern Morocco by dividing prevalence counts by the corresponding population size and multiplying by 100,000 [16]. Five-year prevalence was estimated by counting the number of cases diagnosed in the previous five years and still alive at a given index date [11]. For example, five-year prevalence for 2012 was estimated by counting the number of cases diagnosed between 2008 and 2012 who were still alive at the end of 2012 [11]. We calculated five-year prevalence at three time points for which data were available (2010, 2011, and 2012). The proportions were expressed per 100,000 person [17]. Age-standardized five-year prevalence proportions (per 100,000) were calculated by the direct method, using the world standard population as previously described [17–19]. The age-standardized rate is a summary of the individual age-specific rates using an external population called a standard population. This is the prevalence that would be observed if the population had the age structure of the standard population, and corresponds to the prevalence rate in the standard population [17–19]. National population censuses are conducted in Morocco every 10 years, and the High Commission for Planning provides estimates of the growth rate of the Moroccan population for each year. In this paper, the census conducted in 2004 was used to elaborate the estimates of the population of Eastern Morocco during the period from 2006 to 2012. The annual percent change (APC) was calculated as previously described [17, 20] using the formula: \( \text{APC} = (\exp(B) - 1) \times 100 \), where \( B \) is the parameter estimate obtained on fitting period of events as a continuous variable to the logarithm of the rate.

Ethical approval and authorization for personal data processing

In this study, obtaining informed consent was not possible. So, we were granted a waiver of consent by the Ethical Review Committee, and patient records/information was anonymized and de-identified prior to analysis. Our study protocol was ethically approved by the Ethical Review Committee for Biomedical Research of the Faculty of Medicine and Pharmacy of Casablanca under the number 41/14. The authorization for personal data processing was obtained from the National Commission of control of Personal Data Protection under the number A-RS-280/2014).

Results

9,299 prevalent cases of cancer were registered in the Regional Oncology Centers since it was established in October 2005 until December 2012. Of these, 8,508 cases were residents of Eastern Morocco and were considered in the analysis. 5,779 cases were women and 2,729 men, with a female to male ratio of 2.1. The mean age at diagnosis was 53.9 ± 15.2 years (median age = 53 years) (Table 1).
The sex ratio and the mean age at diagnosis were calculated for each area of Eastern Morocco and the results are shown in Table 1. The areas of Eastern Morocco did not differ significantly by mean age at diagnosis (p = 0.061). However, these regions differed significantly by sex ratio (p < 0.001). The highest sex ratio was observed in Figuig, with a female to male ratio (F/M) of 3.1 (75.4% of the registered case were females), followed respectively by Taourirt with a F/M of 2.4, Oujda-Angad with a F/M of 2.3, Berkane with a F/M of 2.0, Nador-Driouch and Jerada with a F/M of 1.9 each (Table 1).

Clear variation in the distribution of cancer types between areas of Eastern Morocco was observed, both in males and females (p < 0.001). For example, in males, lung cancer is the most frequent cancer type in Oujda-Angad, Nador-Driouch, Berkane, and Figuig (Fig 2; S1 Table). However, this cancer ranked second in Jerada and Taourirt (Fig 2; S1 Table). Similarly, colorectal cancer ranked first in Jerada, second in Oujda-Angad, third in Berkane, fourth in Nador-Driouch, fifth in Figuig and sixth in Taourirt (Fig 2; S1 Table). In the same way, nasopharynx cancer ranked first in Taourirt, second in Nador-Driouch and Berkane, fourth in Oujda-Angad and Jerada, and sixth in Figuig (Fig 2; S1 Table). In women, breast cancer was the most frequent malignancy, followed by cervix uteri cancer in all areas of Eastern Morocco (Fig 3; S2 Table). However, the frequencies of these cancers varied between areas. Indeed, the highest frequency of breast cancer was observed in Nador-Driouch and Berkane (49.5%), followed respectively by Oujda-Angad (48.9%), Taourirt (42.8%), Jerada (42.7%), and Figuig (40.0%) (Fig 3; S2 Table).

Geographic variation in cancer prevalence during the period 2006–2012 was also carried out and the result is shown in Table 2. The areas of Eastern Morocco differed significantly by cancer prevalence proportions (p < 0.001). The highest total prevalence proportion from 2006 to 2012 was observed in Oujda-Angad (660.8 per 100,000), followed respectively by Berkane (497 per 100,000), Jerada (402.7 per 100,000), Taourirt (355.6 per 100,000), Nador-Driouch (275 per 100,000) and Figuig (236.4 per 100,000) (Table 2). Similarly, the highest five-year prevalence proportions during the study period were observed in Oujda-Angad followed respectively by Berkane, Jerada, Taourirt, Nador-Driouch and finally Figuig (Table 2).

Trends in the five-year prevalence proportions in the study period were noticeably different between areas of Eastern Morocco (Fig 4). The five-year cancer prevalence proportion in Oujda-Angad slightly decreased at an APC of 0.6% (Fig 4). In Berkane and Jerada, the five-year prevalence proportion significantly decreased at an APC of 3.1% and 6%, respectively (Fig 4). In contrast, there is a marked increase in the five-year prevalence proportion in Nador-Driouch and Figuig by 5.4% and 5%, respectively (Fig 4). Similarly, the five-year cancer prevalence proportion increased in Taourirt by 1.1% (Fig 4).

Discussion
Cancer is one of the major health problems worldwide [21–23]. Cancer patterns can display great variation between different ethnic populations and areas in the same country [7–13, 24, 25].
Our study showed that there is no significant difference in the mean age at diagnosis between areas of Eastern Morocco. We found that cancer afflict adult population in all areas of Eastern Morocco, with an overall mean age at diagnosis of 53.9 ± 15.2 years (median age = 53 years). In European countries, the largest proportion of all prevalent cases were aged 65 years of age or over [10]. Thus, unlike Western countries, cancer in Eastern Morocco afflicts younger population. This young age phenomenon observed is probably due to the younger population [6]. However, multiple factors may be involved, including genetic and environmental factors. Further studies are needed to confirm the involvement of these factors in the occurrence of cancer at a younger age in Eastern Morocco.

We found that in Eastern Morocco 67.9% of all prevalent cancer cases were females (female to male ratio of 2.1). This high female to male ratio cannot be explained by the structure of the population of Eastern Morocco which showed a sex ratio of female to male of 1.06 during the study period 2006–2012 [6]. This suggests that in Eastern Morocco, women are more afflicted by cancer than men. This female predominance is similar to that reported in European
countries where 61% of all prevalent cancer cases were females[10]. However, in China cancer prevalence estimates were only slightly higher for females compared to males, with a female to male ratio of 1.04[13]. The higher prevalence of cancer in females is most likely attributed to

Table 2. Total and five-year prevalence proportions by area of Eastern Morocco.

<table>
<thead>
<tr>
<th>Period</th>
<th>No. of Cases</th>
<th>All areas</th>
<th>Oujda-Angad</th>
<th>Berkane</th>
<th>Nador-Driouch</th>
<th>Jerada</th>
<th>Taourirt</th>
<th>Figuig</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total prevalence 2006–2012</td>
<td>8248</td>
<td>3284</td>
<td>1391</td>
<td>2053</td>
<td>447</td>
<td>768</td>
<td>305</td>
<td></td>
</tr>
<tr>
<td>Proportion (100,000)</td>
<td>416.7</td>
<td>660.8</td>
<td>497</td>
<td>275</td>
<td>402.7</td>
<td>355.6</td>
<td>236.4</td>
<td></td>
</tr>
<tr>
<td>Five year prevalence 2006–2010</td>
<td>5693</td>
<td>2305</td>
<td>994</td>
<td>1344</td>
<td>328</td>
<td>512</td>
<td>210</td>
<td></td>
</tr>
<tr>
<td>Proportion (100,000)</td>
<td>289.4</td>
<td>467.5</td>
<td>357.6</td>
<td>180.8</td>
<td>298.2</td>
<td>239.3</td>
<td>162.8</td>
<td></td>
</tr>
<tr>
<td>Five year prevalence 2007–2011</td>
<td>5607</td>
<td>2279</td>
<td>947</td>
<td>1395</td>
<td>294</td>
<td>477</td>
<td>215</td>
<td></td>
</tr>
<tr>
<td>Proportion (100,000)</td>
<td>283.2</td>
<td>458.6</td>
<td>338.2</td>
<td>186.8</td>
<td>264.9</td>
<td>220.8</td>
<td>166.7</td>
<td></td>
</tr>
<tr>
<td>Five year prevalence 2008–2012</td>
<td>5833</td>
<td>2315</td>
<td>947</td>
<td>1510</td>
<td>296</td>
<td>533</td>
<td>232</td>
<td></td>
</tr>
<tr>
<td>Proportion (100,000)</td>
<td>292.9</td>
<td>462.1</td>
<td>336.1</td>
<td>201.4</td>
<td>264.3</td>
<td>244.5</td>
<td>179.8</td>
<td></td>
</tr>
</tbody>
</table>


doi:10.1371/journal.pone.0151987.g003
the high prevalence of gynecological and breast cancers. Typically female cancers are usually more common in developing countries as opposed to developed countries [26]. More importantly, the areas of Eastern Morocco differed significantly by sex ratio ($p < 0.001$). The proportion of prevalent cancer cases that were women ranged from 64.4% to 75.4%. The highest sex ratio was observed in Figuig, followed respectively by Taourirt, Oujda-Angad, Berkane, Nador-Driouch and Jerada. A similar geographic variability in sex ratio was observed in Europe where the proportion of prevalent cancer cases that were women ranged from 53% in Spain to 71% in Poland [10]. Further research is needed to understand the sex ratio difference observed between areas of Eastern Morocco.

Remarkable geographic variation in the distribution of cancer types was observed in areas of Eastern Morocco. This variation could be due to differences in the prevalence of risk factors. For example, variation in lung cancer prevalence could be attributed to differences in smoking prevalence among areas, since the association between lung cancer and smoking is well established [27]. Several other risk factors could be involved in this geographic variation in cancer prevalence, like differences in diet, physical activity, lifestyle, genetic factors, and infections prevalence with virus such as human papillomavirus (HPV) or bacteria such as Helicobacter pylori[28–31].

The geographic variation in cancer prevalence could be also due to differences in the use of screening tests. For example, variation in prostate cancer prevalence could be attributed to differences in prostate-specific antigen (PSA) testing prevalence among areas[32, 33]. Likewise, variation in breast cancer prevalence could be partly due to differences in mammography prevalence between areas[34–36]. Therefore, the involvement of the differences in the prevalence of risk factors, use of screening tests, and diagnostic practices must be studied to understand the geographic variation in cancer prevalence observed in Eastern Morocco.

Malignant diseases have been believed to be more common in some areas of Eastern Morocco, but until now, cancer prevalence and incidence have not been reported for this
Thus, our study compared the prevalence of cancer between the areas of Eastern Morocco during the period 2006–2012. The highest total and five-year prevalence proportions were observed in Oujda-Angad followed respectively by Berkane, Jerada, Taourirt, Nador-Driouch and finally Figuig. Furthermore, the areas of Eastern Morocco differed significantly by cancer prevalence proportions. For example, the five-year prevalence proportions from 2008 to 2012 varied between 462.1 per 100,000 in Oujda-Angad and 179.8 per 100,000 in Figuig. Such finding is not very far from that reported in north African countries, where the estimated five-year prevalence proportions for all cancers in area of Eastern Morocco as compared to other North African countries are shown in Table 3.

<table>
<thead>
<tr>
<th>Country</th>
<th>Five year prevalence 2008–2012</th>
<th>Numbers</th>
<th>Proportion (100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eastern Moroccoa</td>
<td></td>
<td>5833</td>
<td>292.9</td>
</tr>
<tr>
<td>Oujda-Angad</td>
<td></td>
<td>2315</td>
<td>462.1</td>
</tr>
<tr>
<td>Berkane</td>
<td></td>
<td>947</td>
<td>336.1</td>
</tr>
<tr>
<td>Nador-Driouch</td>
<td></td>
<td>1510</td>
<td>201.4</td>
</tr>
<tr>
<td>Jerada</td>
<td></td>
<td>296</td>
<td>264.3</td>
</tr>
<tr>
<td>Taourirt</td>
<td></td>
<td>533</td>
<td>244.5</td>
</tr>
<tr>
<td>Figuig</td>
<td></td>
<td>232</td>
<td>179.8</td>
</tr>
<tr>
<td>North African countriesb</td>
<td></td>
<td>463898</td>
<td>323.9</td>
</tr>
<tr>
<td>Morocco</td>
<td></td>
<td>82503</td>
<td>336.1</td>
</tr>
<tr>
<td>Algeria</td>
<td></td>
<td>86382</td>
<td>322.7</td>
</tr>
<tr>
<td>Tunisia</td>
<td></td>
<td>25513</td>
<td>310.1</td>
</tr>
<tr>
<td>Libya</td>
<td></td>
<td>12626</td>
<td>282.4</td>
</tr>
<tr>
<td>Egypt</td>
<td></td>
<td>215486</td>
<td>372.2</td>
</tr>
</tbody>
</table>

aThis study
bEstimated five-year prevalence from the GLOBOCAN project, see http://globocan.iarc.fr

doi:10.1371/journal.pone.0151987.t003

Table 4. Age-standardized five-year prevalence proportions for all cancers in area of Eastern Morocco as compared to other countries.

<table>
<thead>
<tr>
<th>Country</th>
<th>Five year prevalence 2008–2012</th>
<th>Numbers</th>
<th>Proportion (100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eastern Moroccoa</td>
<td></td>
<td>5651</td>
<td>292.9</td>
</tr>
<tr>
<td>Oujda-Angad</td>
<td></td>
<td>2244</td>
<td>420.2</td>
</tr>
<tr>
<td>Berkane</td>
<td></td>
<td>913</td>
<td>311.4</td>
</tr>
<tr>
<td>Nador-Driouch</td>
<td></td>
<td>1463</td>
<td>213.6</td>
</tr>
<tr>
<td>Jerada</td>
<td></td>
<td>289</td>
<td>287.8</td>
</tr>
<tr>
<td>Taourirt</td>
<td></td>
<td>520</td>
<td>269.3</td>
</tr>
<tr>
<td>Figuig</td>
<td></td>
<td>222</td>
<td>194.4</td>
</tr>
<tr>
<td>Nordic countriesb</td>
<td></td>
<td>451163</td>
<td>1738.4</td>
</tr>
<tr>
<td>Danmark</td>
<td></td>
<td>106841</td>
<td>1908.6</td>
</tr>
<tr>
<td>Finland</td>
<td></td>
<td>87126</td>
<td>1605.6</td>
</tr>
<tr>
<td>Iceland</td>
<td></td>
<td>4622</td>
<td>1435.2</td>
</tr>
<tr>
<td>Norway</td>
<td></td>
<td>85854</td>
<td>1701.4</td>
</tr>
<tr>
<td>Sweden</td>
<td></td>
<td>166720</td>
<td>1744.0</td>
</tr>
</tbody>
</table>

aThis study
bAge-standardized five-year prevalence from the NORDCAN project, see http://www-dep.iarc.fr

doi:10.1371/journal.pone.0151987.t004
year prevalence proportions from 2008 to 2012 varied between 372.2 per 100,000 in Egypt and 282.4 per 100,000 in Libya [7, 37, 38] (Table 3).

Large differences in cancer prevalence were also observed between Nordic countries [39, 40]. Indeed, the age-standardized five-year prevalence proportions for all cancers varied between 1908.6 per 100,000 in Danmark and 1435.2 per 100,000 in Iceland (Table 4) [39, 40]. It is worth noting that the age-standardized five-year prevalence proportions observed in this study were much lower than those reported in Nordic countries (Table 4) [39, 40]. Large differences in cancer prevalence were also observed between European countries as well as between United States [8, 10, 25].

Trends in the five-year prevalence proportions were also analyzed during the study period. We found a noticeable difference in cancer prevalence between areas of Eastern Morocco. Indeed, the five-year prevalence proportions decreased in Oujda-Angad, Berkane and Jerada. However, there was a moderate increase in the five-year prevalence proportions in Taourirt, and a marked increase in the regions of Nador-Driouch, and Figuig. It is worth noting that the geographic variation in cancer prevalence presented in this study may be influenced by differences in the accessibility to care at the Regional Oncology Center of Oujda. Moreover, cancer prevalence is a function of the incidence, survival and population demographics [9]. Therefore, our data is a very first step to understand cancer prevalence in Eastern Morocco and further extensive studies are necessary to better understand the reasons for the geographic variability in cancer prevalence among areas of Eastern Morocco.

**Conclusion**

This study of a large number of patients diagnosed with cancer is a very first step to understand the geographic variability in cancer prevalence in Eastern Morocco. The areas of Eastern Morocco differed significantly by the distribution pattern of major cancer sites, sex ratio, and trends in cancer prevalence. These findings justify the need to establish a regional cancer registry as a first step to better understand this geographic variability in cancer prevalence in Eastern Morocco. The findings highlight also the need to develop program aiming at controlling and preventing the spread of major cancer sites in Eastern Morocco, particularly in areas with increased cancer prevalence rates.

**Supporting Information**

S1 Table. Distribution pattern of cancer in males by area of Eastern Morocco, October 2005-December 2012.

(PDF)


(PDF)

**Acknowledgments**

We are grateful to the clinical team and to all administrative staff at Hassan II Regional Oncology Center of Oujda for their support. We also thank the Regional Director of the Ministry of Health in Eastern Morocco for his support. We thank Dr. A. Azzouzi and all the administrative staff of the Faculty of Medicine and Pharmacy of Oujda for their valuable support and encouragement throughout the entire work.
Author Contributions
Conceived and designed the experiments: Manal Elidrissi Errahhali Mounia Elidrissi Errahhali MB. Performed the experiments: Manal Elidrissi Errahhali Mounia Elidrissi Errahhali MB. Analyzed the data: Manal Elidrissi Errahhali Mounia Elidrissi Errahhali MB. Wrote the paper: Manal Elidrissi Errahhali Mounia Elidrissi Errahhali MB. Participated in interpreting the data and in revising the manuscript: Manal Elidrissi Errahhali Mounia Elidrissi Errahhali NA MB.

References
2. DPRF. Santé en chiffre 2012: Ministère de la Santé; 2014.


